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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the evidence for the benefit of palliative pharmacological sedation on quality of life and specific refractory symptoms in
terminally ill adults.
B A C K G R O U N D
Description of the condition
Terminally ill patients experience a variety of symptoms in the
last hours and days of life, including delirium, agitation, anxiety,
terminal restlessness, dyspnoea, pain, vomiting, and psychologi-
cal and physical distress. Terminal restlessness is an agitated delir-
ium that occurs in some patients during the last few days of life
(Doyle 2008). A Study to Understand Prognoses and Preferences
for Outcomes and Risks of Treatments (SUPPORT) (Lynn 1997)
indicated that during their last three days of life, 80% of dying
hospitalised patients suffered severe fatigue, 50% severe dyspnoea,
and 40% severe pain. In another study, the most commonly re-
ported symptoms were fatigue, dyspnoea and dry mouth, with
the most distressing being fatigue, dyspnoea and pain (Hickman
2001). Other distressing symptoms reported in this and other sim-
ilar studies were noisy breathing, excess respiratory secretions, ag-
itation, anxiety, constipation, nausea and vomiting, anorexia, in-
continence, pressure sores, and insomnia.
In the terminal phase of life (i.e. when the disease is progressive,
far advanced, and incurable), these symptoms may become refrac-
tory, unable to be controlled by supportive and palliative therapies
specifically targeted to these symptoms. Palliative sedation therapy
is one potential solution to providing relief from these refractory
symptoms.
Description of the intervention
Palliative sedation therapy has been described as ’the use of sedative
medications to relieve intolerable suffering from refractory symp-
toms by a reduction in patient consciousness’ (De Graeff 2007).
The therapy can vary in terms of level of sedation (mild, inter-
mediate, and deep), and duration (intermittent or continuous).
Sedation can be achieved by drugs that are primarily sedatives, and
are not designed to treat the underlying condition or symptom,
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or by drugs that have some effect on the underlying symptom and
have a secondary effect of causing somnolence.
Drug classes used for palliative sedation include benzodiazepines
(particularly midazolam and clonazepam), antipsychotics, opioids
and hypnotics. They may be administered intravenously or sub-
cutaneously.
How the intervention might work
Sedation in the terminally ill is intended to provide relief from
refractory symptoms that are not controlled by other means. Seda-
tive drugs such as benzodiazepines and propofol are easily and
rapidly titrated to achieve the desired level of sedation; the level of
sedation can be maintained and the effect is reversible. Therefore
sedation may be useful in terminally ill patients where symptom
control cannot be achieved by drugs targeted at the specific symp-
tom.
Why it is important to do this review
There are existing Cochrane reviews on interventions for partic-
ular symptoms (e.g. interventions for noisy breathing in patients
near to death (Wee 2008), opioids for palliation of breathlessness
(Jennings 2011), drug therapy for delirium in the terminally ill
(Jackson 2004a), benzodiazepines and related drugs for insomnia
in palliative care (Hirst 2009), anxiety in palliative care (Jackson
2004b)), and a systematic review of one drug (propofol) for ter-
minal sedation (McWilliams 2010). However. this review aims to
bring together in one place the limited information on all drugs
used to sedate terminallyill patients, for all symptoms, specifically
in the terminal phase of life, as distinct from the broader palliative
care setting.
O B J E C T I V E S
To assess the evidence for the benefit of palliative pharmacological
sedation on quality of life and specific refractory symptoms in
terminally ill adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), quasi-RCTs, non-RCTs,
and observational studies (e.g. before-and-after, interrupted-time-
series) with quantitative outcomes. This choice has been made be-
cause of the lack of RCTs in this area. We will exclude studies with
only qualitative outcomes.
Types of participants
Wewill include studies that include adult (>= 15 years), terminally
ill patients who require sedation in order to control any symp-
tom(s) (e.g. agitation, anxiety, insomnia, terminal restlessness, dys-
pnoea, pain). We will consider all terminal conditions (malignant
and non-malignant), in all settings (e.g. home, hospital, palliative
care institution).
Types of interventions
Anymedication with a sedative effect (e.g. benzodiazepines, barbi-
turates, anaesthesia, opioids, antipsychotics, antihistamines, other
hypnotics) where the intent is sedation for symptom relief.
Types of outcome measures
Primary outcomes
1. Quality of life or patient well-being. This will usually be
measured by a proxy (e.g. doctor, nurse, carer), but in certain
circumstances may be measured by the patient during periods of
adequate consciousness.
Secondary outcomes
1. Control of specific symptom(s) (e.g. agitation, anxiety,
insomnia, terminal restlessness, dyspnoea, pain).
2. Duration of symptom control.
3. Time to control of symptoms.
4. Adverse effects of treatment. For example, for antipsychotics
these may include: worse drowsiness than intended,
extrapyramidal effects, akathisia (restlessness), neuroleptic
malignant syndrome, urinary retention, and constipation; and
for benzodiazepines: drowsiness, ataxia, confusion, falls,
increased restlessness, respiratory depression, and hypotension.
5. Duration of institutional care.
6. Time to death.
7. Carer satisfaction.
Search methods for identification of studies
Electronic searches
We will search the following databases.
1. The Cochrane Pain, Palliative and Supportive Care Register
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2. The Cochrane Central Register of Controlled Trials
(CENTRAL)
3. MEDLINE (1946 to present)
4. EMBASE (1974 to present)
The MEDLINE strategy is shown in Appendix 1; we will adapt
the MEDLINE search for other databases.
We will also search clinical trials registries (ClinicalTrials.gov;
WHO Trials Registry) to find any ongoing trials or to locate other
publications that might not have been found in the database
searches.
Searching other resources
1. Reference lists of relevant textbooks, review articles and
relevant studies.
2. We will write to investigators known to be involved in
previous studies, seeking information about unpublished or
incomplete trials.
Data collection and analysis
Selection of studies
We will use the search strategy described to obtain titles and ab-
stracts of studies that may be relevant to the review. Two authors
(EB, MvD) will independently screen the titles and abstracts, and
discard studies that are not applicable; we will, however, initially
retain studies and reviews that might include relevant data or in-
formation on studies.
Two review authors (EB, MvD) will independently assess the re-
trieved full-text of these studies to determine which studies satisfy
the inclusion criteria. A third review author will act as arbiter if
needed (GM).
Data extraction and management
Two review authors (EB, MvD) will independently carry out data
extraction using standard data extraction forms. We will translate
studies reported in non-English language journals before assess-
ment. Where more than one publication of one study exists, we
will group reports together and only use the publication with the
most complete data in the analyses. Where relevant outcomes are
only published in earlier versions, we will use these data. We will
highlight any discrepancy between published versions. A third re-
view author will act as arbiter if needed (GM). RevMan 5 analy-
sis software will be used to enter data and perform meta-analyses
(EB).
Assessment of risk of bias in included studies
For RCTs, two review authors (EB, MvD) will independently as-
sess the following items using the Cochrane ’Risk of bias’ assess-
ment tool (Higgins 2011). A third review author (GM) will act as
arbiter if needed.
• Adequate sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other bias
For non-randomised, comparative trials, the first and second cri-
teria will be set to “high risk of bias”. Two additional criteria to
assess selection bias will be included:
• Were baseline characteristics similar?
• Were baseline outcome measurements similar?
This follows the recommendations of theCochrane Effective Prac-
tice and Organisation of Care (EPOC) review group for assessing
risk of bias in non-randomised studies.
We will assess each of these criteria as low risk of bias, unclear risk
of bias, or high risk of bias.
Measures of treatment effect
Primary Outcomes
Quality of life or patient well-being
We anticipate studies will measure this on a recognised quality of
life continuous scale. Since there are many quality of life scales, we
will use the standardised mean difference (SMD) (with standard
deviation) between the intervention and control groups to include
all comparative studies with a quality of life scale or well-being
scale as outcome.
Secondary Outcomes
Symptom control
Where studies report this on a continuous scale, we will use SMD
(with 95% confidence interval (CI)) to combine them in a similar
fashion to the primary outcome.
Where studies report this on a dichotomous scale (e.g. relief versus
no relief ), we will combine these studies using risk ratio (RR)
(relative risk) in the intervention group compared with control
(with 95% CI).
If data are reported using a short ordinal scale (e.g. no relief, some
relief, moderate relief, good relief ), we will consider combining
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the moderate and good relief categories, and the none and mild
categories and include these with the dichotomous outcome stud-
ies if appropriate.
Adverse effects of treatment
We will use the proportion of participants experiencing any ad-
verse effect of treatment, and combine studies using RR (and 95%
CI), as for the symptom control outcome above. We will also re-
port descriptively the number of each type of adverse event (i.e.
unintended effects of treatment).
Duration of symptom control, time to control of symptoms,
duration of institutional care, time to death
If there are sufficient studies to meta-analyse these outcomes, we
will use the generic inverse variance method to pool hazard ratios
(Higgins 2011).
Carer satisfaction
We will pool studies where this is reported in a similar fashion to
the quality of life and well-being outcome described above.
For single-arm studies, we will tabulate the results in a descriptive
form.
Unit of analysis issues
It is unlikely that any studies in this area will utilise a cluster or
cross-over design, so the unit of randomisation or allocation will
generally be the individual patient.
Dealing with missing data
We will request any further information required from the study
authors by written correspondence (e.g. emailing and/or writing
to corresponding author(s)) and we will include any relevant in-
formation obtained in this manner in the review. We will carefully
perform an evaluation of important numerical data such as num-
bers of patients screened, numbers of randomised patients, as well
as numbers in the intention-to-treat (ITT), as-treated and per-
protocol (PP) populations. We will investigate attrition rates, for
example drop-outs, losses to follow-up and withdrawals. We will
critically appraise issues of missing data and imputation methods
(for example, last-observation-carried-forward (LOCF)) (Higgins
2011).
Assessment of reporting biases
Wewill assess the potential for publicationbias by checking clinical
trials registers for unpublished studies. If more than twenty studies
are found, we will use the funnel plot statistic and funnel plots
to assess for the potential existence of small study bias (Higgins
2011).
Data synthesis
We will pool data using the random-effects model as we expect
heterogeneity of treatments and participants, but we will also use
the fixed-effect model to evaluate robustness of the model chosen
and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
We will undertake subgroup analyses according to:
1. the condition causing the need for palliative care i.e.
malignant versus non-malignant;
2. drug class; and
3. main symptom being treated.
We will assess heterogeneity using the I2 statistic, and make a
decision to either:
1. combine studies using a random-effects method (where the
I2 statistic is low to moderate, and the studies appear to be
reasonably similar); or
2. not combine all studies (where either the I2 statistic is
moderate and reasons for heterogeneity are plausible and
therefore indicate that combining studies is not appropriate, or
the I2 statistic is high). In the first case, we may undertake post
hoc subgroup analyses if sufficient studies exist in each subgroup
of the plausible heterogeneity factor.
In investigating heterogeneity of the included studies, we will in-
clude treatment factors such as the continuation or weaning of se-
dation, degree of sedation achieved, timing and dosage of medica-
tion, and study design factors such as the length of follow-up, type
of proxy used for quality of lifemeasurement, and time of outcome
measurement.We will describe these factors in the ’Characteristics
of included studies’ table.
Sensitivity analysis
Since we plan to include any quasi-randomised and non-ran-
domised comparative studies we find, we will investigate the effect
of omitting those studies on the results using sensitivity analysis.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 exp Central Nervous System Depressants/
2 exp Anesthesia/
3 exp Benzodiazepines/
4 exp Barbiturates/
5 exp Histamine Antagonists/
6 exp Psychotropic Drugs/
7 (benzodiazepine* or barbiturate* or anaesthesia or anesthesia or opioid* or antipsychotic* or anti-psychotic* or antihistamine* or
anti-histamine* or hypnotic* or sedat* or tranquil*).mp.
8 (symptom* adj6 (relie* or control*)).mp.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 Palliative Care/
11 exp Terminal Care/
12 Terminally Ill/
13 palliat*.mp.
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14 (terminal* adj6 (care or caring or ill*)).mp.
15 (terminal-stage* or terminal stage* or dying or (close adj6 death)).mp.
16 (end adj3 life).mp.
17 hospice*.mp.
18 ((end-stage* or end stage*) adj6 (disease* or ill* or care or caring)).mp.
19 ((incurable or advanced) adj6 (ill* or disease*)).mp.
20 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 9 and 20
22 randomized controlled trial.pt.
23 controlled clinical trial.pt.
24 randomized.ab.
25 placebo.ab.
26 clinical trials as topic.sh.
27 randomly.ab.
28 trial.ti.
29 exp Cohort Studies/
30 (cohort* or observational* or comparative* or quantitative* or (before and after) or (interrupted and time)).mp.
31 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 21 and 31
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